Levels of Circulating Fibroblast Growth Factor 23 (FGF23) and Prognosis in Cancer Patients with Bone Metastases

The fibroblast growth factor (FGF) signaling pathway plays a key role in tumorigenesis and is recognized as a potential therapeutic target. In this study, the authors aimed to assess the impact of serum FGF23 levels in the prognosis of patients with cancer and bone metastases from solid tumors. A co...

Full description

Saved in:
Bibliographic Details
Published in:International journal of molecular sciences 2019-02, Vol.20 (3), p.695
Main Authors: Mansinho, André, Ferreira, Arlindo R, Casimiro, Sandra, Alho, Irina, Vendrell, Inês, Costa, Ana Lúcia, Sousa, Rita, Abreu, Catarina, Pulido, Catarina, Macedo, Daniela, Pacheco, Teresa R, Correia, Lurdes, Costa, Luís
Format: Article
Language:English
Subjects:
Angiogenesis
Antagonists
Biomarkers
Bone cancer
bone metastases
Breast cancer
cancer
Cell proliferation
Chemotaxis
FGF23
Fibroblast growth factor 23
Fibroblast growth factor receptors
Fibroblasts
Growth factors
Medical prognosis
Metastases
Metastasis
Morphogenesis
Oncology
Patients
Population studies
Prognosis
Prostate cancer
Serum levels
Standard deviation
Studies
Survival analysis
Thyroid
Tumorigenesis
Tumors
Urine
Vitamin D
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The fibroblast growth factor (FGF) signaling pathway plays a key role in tumorigenesis and is recognized as a potential therapeutic target. In this study, the authors aimed to assess the impact of serum FGF23 levels in the prognosis of patients with cancer and bone metastases from solid tumors. A cohort of 112 patients with cancer and metastatic bone disease were treated with bone-targeted agents (BTA). Serum baseline FGF23 was quantified by ELISA and dichotomized in FGF23 and FGF23 groups. Additionally, the association between FGF23 and overall survival (OS) and time to skeletal-related events (TTSRE) was investigated. Baseline characteristics were balanced between groups, except for the median urinary N-terminal telopeptide (uNTX) level. After a median follow-up of 26.0 months, a median OS of 34.4 and 12.2 months was found in the FGF23 and FGF23 groups, respectively (multivariate HR 0.18, 95% CI 0.07⁻0.44, = 0.001; univariate HR 0.27, = 0.001). Additionally, TTSRE was significantly longer for patients with FGF23 (13.0 vs 2.0 months, = 0.04). Overall, this study found that patients with FGF23 at baseline had longer OS and TTSRE. Further studies are warranted to define its role as a prognostic biomarker and in the use of drugs targeting the FGF axis.
ISSN:1422-0067
1661-6596
1422-0067
DOI:10.3390/ijms20030695